E.g., 08/19/2019
E.g., 08/19/2019
Titlesort ascending Category Credit Event date Price
Immuno-Oncology: A New Class of Drugs Webcast (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals. The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Immuno-Oncology: A Focus on Prostate Cancer Webcast (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals. This is the fourth in a series of 4 webinars.
Immuno-Oncology: A Focus on Kidney Cancer Webcast (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals. The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Immuno-Oncology: A Focus on Bladder Cancer Webcast (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals. The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Highlights in the Medical Management of Urothelial Carcinoma: Non-Muscle Invasive Urothelial Carcinoma (2019)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The Live from AUA2019: Highlights in the Medical Management of Urothelial Carcinoma is compromised of two panel discussions filmed at the 2019 AUA Annual Meeting in Chicago focused on optimizing the treatment of urothelial carcinoma.  The panel discussions will present the latest developments in the:1) Management of Non-Muscle Invasive Urothelial Carcinoma 2) Management of Advanced and Metastatic Urothelial Carcinoma (see below for a link to the activity)
Highlights in the Medical Management of Urothelial Carcinoma: Advanced and Metastatic Urothelial Carcinoma (2019)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The Live from AUA2019: Highlights in the Medical Management of Urothelial Carcinoma is compromised of two panel discussions filmed at the 2019 AUA Annual Meeting in Chicago focused on optimizing the treatment of urothelial carcinoma.  The panel discussions will present the latest developments in the:1) Management of Non-Muscle Invasive Urothelial Carcinoma (see below for a link to the activity)2) Management of Advanced and Metastatic Urothelial Carcinoma
Highlights in Renal Cell Carcinoma: The Roles of the Urologist and Medical Oncologist (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Highlights in Renal Cell Carcinoma: The Evolving Landscape of Adjuvant Therapy (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Highlights in Renal Cell Carcinoma: Coordination of Care & the Patient's Journey (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Highlights from AUA2019: Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer (2019) $0.00 Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).
Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease & CRPC Webcast 013IC (2019)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g.
Fundamentals in Urology Webcast (2019) $655.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
Female Sexual Dysfunction for APPs (2017)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$40.00 Member only benefit! The prevalence of Female Sexual Dysfunction (FSD) a disease encompassing sexual desire and arousal disorders, orgasmic disorders, and sexual pain disorders, is a complex and important clinical issue. In the National Health and Social Life Survey, 43% of women reported some degree of sexual difficulty. There is a disparity in the treatment of sexual dysfunction between women and men that is now correcting.
Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer: A Guidelines and Case-Based Discussion - Washington, D.C. (...
  • 5.75 AMA PRA Category 1 Credit™
  • 5.75 Non-Physician Participation
12/03/2019 $0.00 Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).
Emerging Treatment Options for Non-Metastatic CRPC Podcast (2018)
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation has produced a series of online activities and educational resources for healthcare professionals, patients and caregivers. One of those such activities is this complimentary Emerging Treatment Options for Non-Metastatic CRPC Podcast (2018).

Pages